These results strongly suggested that modulation of the transcriptional activity of specific promoters in response to the local release or perturbation of chromatin structure, by treatment with HDAC inhibitors, could effectively prevent the synovial proliferation and joint destruction seen in human RA. Here, HDAC9 is linked to rheumatoid arthritis.